Fund moves

Royalty Pharma (RPRX): Viking Global exited its position 2.6M shares

Viking Global exited its position in Royalty Pharma, per its Q3 2025 13F.

2.6M
Prior-quarter shares · no longer reported
Holdings as of
Sep 30, 2025
Filed
Nov 14, 2025

What stands out in this filing

  • The manager reported no shares in Q3 2025, after 2,597,460 in its Q2 2025 filing.
  • 8 other tracked managers reported the same kind of change for Q3 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 16, 2025Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  2. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results

What came next

  1. Nov 17, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
  2. Nov 19, 2025Insider · 1 personInsiders: 8 sales (~$5.2M)
  3. Nov 24, 2025Insider · 1 personInsiders: 4 sales (~$2.7M)
  4. Dec 1, 2025Insider · 2 peopleInsiders: 4 sales (~$4.4M)
  5. Dec 3, 2025InsiderOfficer sold ~$4.38M of RPRX shares in the open market
  6. Dec 5, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
  7. Dec 15, 2025Insider · 1 personInsiders: 2 sales (~$2.7M)
  8. Dec 16, 2025InsiderOfficer sold ~$766K of RPRX shares in the open market
  9. Dec 17, 2025InsiderOfficer sold ~$3.06M of RPRX shares in the open market
  10. Dec 18, 2025InsiderOfficer sold ~$1.18M of RPRX shares in the open market
  11. Dec 19, 2025InsiderOfficer sold ~$768K of RPRX shares in the open market
  12. Dec 20, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 20, 2025, George W. Lloyd, age 66, informed Royalty Pharma plc (the “Company”) of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025.”
  13. Dec 26, 2025InsiderOfficer sold ~$786K of RPRX shares in the open market
  14. Jan 2, 2026Insider · 2 peopleInsiders: 3 sales (~$3.4M)
  15. Jan 9, 2026InsiderOfficer sold ~$816K of RPRX shares in the open market
  16. Jan 16, 2026InsiderOfficer sold ~$790K of RPRX shares in the open market
  17. Jan 20, 2026Insider · 1 personInsiders: 2 sales (~$2.7M)
  18. Jan 23, 2026InsiderOfficer sold ~$805K of RPRX shares in the open market
  19. Jan 30, 2026InsiderOfficer sold ~$822K of RPRX shares in the open market
  20. Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$4.6M)
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Royalty Pharma

For Royalty Pharma, OQRO holds 16 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RPRX page.

How this filing works

Explore the data

Common questions

What does this filing report about Royalty Pharma (RPRX) stock?

Viking Global exited its position in Royalty Pharma, per its Q3 2025 13F. Held the prior quarter, no longer listed per its Q3 2025 13F.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.

What stands out in this filing?

The manager reported no shares in Q3 2025, after 2,597,460 in its Q2 2025 filing. 8 other tracked managers reported the same kind of change for Q3 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Royalty Pharma recently?

For Royalty Pharma, OQRO holds 16 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the RPRX page.

Does this mean RPRX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Royalty Pharma

Everything OQRO holds on this company is on its RPRX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data